The FDA Commissioner Tried to Kill a Drug Approval. His Own Staff Said No.

That's what makes the commissioner's reported intervention so jarring. If the science was solid and the review was essentially done, what exactly was the basis for rejection?

A Pattern, Not an Incident

This story doesn't exist in a vacuum. It lands in the middle of a much larger debate about who actually makes approval decisions at the FDA in 2026.

Commissioner Makary has introduced a National Priority Voucher program that can push certain drugs to approval in as little as one to two months, far faster than the standard timeline. Supporters say it gets life-saving treatments to patients sooner. Critics, both inside the agency and in the broader industry, worry that speed is coming at the expense of scientific rigor.

The deeper concern isn't just about pace. It's about who holds the pen. Multiple reports indicate that approval decisions under the voucher program are being made by senior agency leaders (read: political appointees) rather than the career scientific reviewers who traditionally run the show. Former FDA officials have told reporters that the agency's decision-making has become more opaque.

Robert Califf, who served as FDA commissioner before Makary, warned about exactly this scenario. In a January 2025 interview, Califf said he didn't think political appointees should intervene in individual FDA decisions, asking pointedly: "Where does it stop?" By March 2026, Califf was calling political influence at the agency "a serious problem."

The KalVista situation looks like a case study of those fears coming true. A commissioner-level figure reportedly tried to override the scientific review process on a specific drug. Career staff had to act as the guardrail.

Why Every Biotech Company Should Be Nervous

If you're a biotech CEO with a drug under FDA review right now, this story should keep you up at night. Not because your drug is likely to get torpedoed by the commissioner personally, but because the possibility now exists in a way it didn't before.

The FDA's credibility rests on a simple premise: decisions are based on science, not politics. Companies spend hundreds of millions of dollars and years of development time operating under that assumption. Investors price stocks based on it. Patients trust their medicines because of it.

When that premise wobbles, the ripple effects are enormous. Reuters has reported that some drugmakers worry fast-tracked approvals could create legal risk if later challenged in court, or if safety problems surface after launch. The flip side is equally troubling: if a commissioner can push to reject a drug over the objections of reviewers, what's the scientific standard anymore?

KalVista's stock tells an interesting story of its own. Analysts remain split, with consensus ranging from Hold to Buy. JMP and Stifel have both raised targets on strong EKTERLY demand, while H.C. Wainwright cut to Neutral after a merger announcement. The fact that sebetralstat eventually got approved suggests the system's safeguards worked this time. But "this time" is doing a lot of heavy lifting in that sentence.

The Bigger Picture

The KalVista episode is unfolding alongside another high-profile FDA review: Sarepta Therapeutics' Elevidys, a gene therapy for Duchenne muscular dystrophy. The FDA identified two fatal cases of acute liver failure linked to Sarepta's products, leading to a boxed warning and restrictions limiting the drug to ambulatory patients aged 4 and older. That's a case where aggressive FDA scrutiny arguably should increase. It involves patient deaths and acute liver failure.

Put the two stories side by side and you see the tension clearly. The FDA needs the independence to investigate real safety signals aggressively (Sarepta) while also keeping political fingers off the scale when the science is clean (KalVista). Those two things require the same ingredient: letting career scientists lead.

Califf's predecessor-era FDA approved 23 of 46 new drugs in 2025 with Orphan Drug Designation, showing the agency can move quickly on rare diseases when evidence supports it. Speed and scientific rigor aren't enemies. But speed directed by political appointees, bypassing the people who actually read the data? That's a different animal entirely.

The guardrails held at KalVista. The career scientists said no, and the rejection request went away. EKTERLY made it to market. But the fact that the guardrails were tested at all is the story. Because next time, the scientists might not win.

GSK's Flu Shot Just Beat the Old Guard. Now Comes the Hard Part.

GSK's mRNA flu vaccine outperformed standard shots in Phase 2 and is heading to a pivotal Phase 3 trial. But history shows that better antibodies don't always mean better protection, and the road ahead is full of trap doors.